Symbols / EXAS
EXAS Chart
About
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 19.73B |
| Enterprise Value | 21.30B | Income | -207.95M | Sales | 3.25B |
| Book/sh | 12.58 | Cash/sh | 5.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7100 | IPO | — |
| P/E | — | Forward P/E | 54.97 | PEG | — |
| P/S | 6.08 | P/B | 8.21 | P/C | — |
| EV/EBITDA | 298.06 | EV/Sales | 6.56 | Quick Ratio | 1.97 |
| Current Ratio | 2.43 | Debt/Eq | 105.57 | LT Debt/Eq | — |
| EPS (ttm) | -1.10 | EPS next Y | 1.88 | EPS Growth | — |
| Revenue Growth | 23.10% | Earnings | 2026-05-07 | ROA | -1.59% |
| ROE | -8.66% | ROIC | — | Gross Margin | 69.69% |
| Oper. Margin | -9.28% | Profit Margin | -6.40% | Shs Outstand | 190.89M |
| Shs Float | 188.46M | Short Float | 3.78% | Short Ratio | 2.99 |
| Short Interest | — | 52W High | 103.67 | 52W Low | 38.81 |
| Beta | 1.44 | Avg Volume | 2.83M | Volume | 1.78M |
| Target Price | $105.81 | Recom | Hold | Prev Close | $103.38 |
| Price | $103.35 | Change | -0.03% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$105.81
Mean price target
2. Current target
$103.35
Latest analyst target
3. DCF / Fair value
$26.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$103.35
Low
$105.00
High
$118.00
Mean
$105.81
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-20 | down | Mizuho | Outperform → Neutral | $105 |
| 2026-01-05 | down | Evercore ISI Group | Outperform → In-Line | $105 |
| 2025-11-28 | down | Stifel | Buy → Hold | $105 |
| 2025-11-25 | down | Canaccord Genuity | Buy → Hold | $105 |
| 2025-11-24 | down | Benchmark | Buy → Hold | — |
| 2025-11-24 | down | Jefferies | Buy → Hold | $105 |
| 2025-11-21 | down | Wells Fargo | Overweight → Equal-Weight | $105 |
| 2025-11-21 | down | William Blair | Outperform → Market Perform | — |
| 2025-11-21 | down | Guggenheim | Buy → Neutral | — |
| 2025-11-21 | down | Barclays | Overweight → Equal-Weight | $105 |
| 2025-11-20 | down | BTIG | Buy → Neutral | — |
| 2025-11-11 | main | Piper Sandler | Overweight → Overweight | $80 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $85 |
| 2025-11-04 | main | TD Cowen | Buy → Buy | $90 |
| 2025-11-04 | main | Baird | Outperform → Outperform | $88 |
| 2025-11-04 | main | Benchmark | Buy → Buy | $75 |
| 2025-11-04 | main | Guggenheim | Buy → Buy | $75 |
| 2025-11-04 | main | Barclays | Overweight → Overweight | $77 |
| 2025-11-04 | main | Stifel | Buy → Buy | $80 |
| 2025-11-04 | main | BTIG | Buy → Buy | $85 |
- Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C. - MarketBeat ue, 03 Mar 2026 10
- Exact Sciences Corporation (EXAS) Stock Analysis: Evaluating Growth Prospects Amidst Strong Revenue Growth - DirectorsTalk Interviews Mon, 02 Mar 2026 17
- Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus - simplywall.st ue, 03 Mar 2026 11
- EXAS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sun, 01 Mar 2026 15
- Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Yahoo Finance Fri, 27 Feb 2026 21
- Champlain Investment Partners LLC Sells 159,186 Shares of Exact Sciences Corporation $EXAS - MarketBeat ue, 03 Mar 2026 10
- December 18th Options Now Available For EXACT Sciences (EXAS) - Nasdaq Fri, 27 Feb 2026 15
- Pentwater Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus Sat, 28 Feb 2026 20
- Exact Sciences (EXAS) grants SVP Herriott 20,321 restricted stock units - Stock Titan Fri, 27 Feb 2026 21
- CSLLY vs. EXAS: Which Stock Is the Better Value Option? - Yahoo Finance Mon, 16 Feb 2026 08
- Exact Sciences Corporation (EXAS) Stock Analysis: Navigating the Diagnostic Frontier with a 2.3% Upside Potential - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Should You Continue to Hold EXAS Stock in Your Portfolio Now? - Nasdaq ue, 30 Dec 2025 08
- Assessing Exact Sciences (EXAS) Valuation After A Strong 1 Year Shareholder Return - simplywall.st hu, 26 Feb 2026 00
- Exact Sciences (NASDAQ: EXAS) EVP receives 38,707 restricted stock units - Stock Titan Fri, 27 Feb 2026 21
- DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS - MarketBeat Sun, 01 Mar 2026 09
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 13181 | — | — | Stock Award(Grant) at price 0.00 per share. | CONROY KEVIN T | Chief Executive Officer | — | 2026-02-25 00:00:00 | D |
| 1 | 92523 | — | — | Stock Award(Grant) at price 0.00 per share. | BARANICK BRIAN | Officer | — | 2025-12-24 00:00:00 | D |
| 2 | 72320 | — | — | Stock Award(Grant) at price 0.00 per share. | HERRIOTT JAMES | General Counsel | — | 2025-12-23 00:00:00 | D |
| 3 | 33780 | nan | — | — | HERRIOTT JAMES | General Counsel | — | 2025-12-23 00:00:00 | D |
| 4 | 63099 | nan | — | — | BLOOMER AARON | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 5 | 42018 | — | — | Stock Award(Grant) at price 0.00 per share. | CONDELLA SARAH K | Officer | — | 2025-12-23 00:00:00 | D |
| 6 | 47208 | nan | — | — | CONDELLA SARAH K | Officer | — | 2025-12-23 00:00:00 | D |
| 7 | 73080 | nan | — | — | BARANICK BRIAN | Officer | — | 2025-12-23 00:00:00 | D |
| 8 | 72523 | — | — | Stock Award(Grant) at price 0.00 per share. | ORVILLE JACOB A | Officer | — | 2025-12-23 00:00:00 | D |
| 9 | 73080 | nan | — | — | ORVILLE JACOB A | Officer | — | 2025-12-23 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 7.26M | -4.92M | 8.91M | -460.12K |
| TaxRateForCalcs | 0.21 | 0.01 | 0.21 | 0.01 |
| NormalizedEBITDA | 17.87M | 30.32M | -13.13M | -385.71M |
| TotalUnusualItems | 34.57M | -819.65M | 42.42M | -35.39M |
| TotalUnusualItemsExcludingGoodwill | 34.57M | -819.65M | 42.42M | -35.39M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -207.95M | -1.03B | -204.15M | -623.51M |
| ReconciledDepreciation | 221.58M | 214.86M | 206.61M | 197.56M |
| ReconciledCostOfRevenue | 984.24M | 840.15M | 737.56M | 661.36M |
| EBITDA | 52.44M | -789.33M | 29.28M | -421.11M |
| EBIT | -169.14M | -1.00B | -177.32M | -618.66M |
| NetInterestIncome | -39.36M | -37.27M | -29.77M | -19.63M |
| InterestExpense | 34.75M | 31.97M | 24.42M | 13.91M |
| NormalizedIncome | -235.26M | -214.13M | -237.66M | -588.57M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -207.95M | -1.03B | -204.15M | -623.51M |
| TotalExpenses | 3.45B | 2.94B | 2.71B | 2.66B |
| TotalOperatingIncomeAsReported | -206.30M | -1.05B | -215.01M | -593.51M |
| DilutedAverageShares | 188.69M | 184.20M | 180.14M | 176.35M |
| BasicAverageShares | 188.69M | 184.20M | 180.14M | 176.35M |
| DilutedEPS | -1.10 | -5.59 | -1.13 | -3.54 |
| BasicEPS | -1.10 | -5.59 | -1.13 | -3.54 |
| DilutedNIAvailtoComStockholders | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncomeCommonStockholders | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncome | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncomeIncludingNoncontrollingInterests | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncomeContinuousOperations | -207.95M | -1.03B | -204.15M | -623.51M |
| TaxProvision | 4.06M | -7.30M | 2.40M | -9.06M |
| PretaxIncome | -203.89M | -1.04B | -201.75M | -632.57M |
| OtherIncomeExpense | 34.57M | -819.65M | 42.42M | -35.39M |
| SpecialIncomeCharges | -7.20M | -859.21M | 9.70M | -15.97M |
| OtherSpecialCharges | -10.25M | -10.32M | ||
| ImpairmentOfCapitalAssets | 7.20M | 869.46M | 621.00K | 15.97M |
| GainOnSaleOfSecurity | 41.77M | 39.56M | 32.71M | -19.43M |
| NetNonOperatingInterestIncomeExpense | -39.36M | -37.27M | -29.77M | -19.63M |
| TotalOtherFinanceCost | 4.61M | 5.30M | 5.35M | 5.73M |
| InterestExpenseNonOperating | 34.75M | 31.97M | 24.42M | 13.91M |
| OperatingIncome | -199.10M | -179.24M | -214.39M | -577.54M |
| OperatingExpense | 2.46B | 2.10B | 1.98B | 2.00B |
| OtherOperatingExpenses | -9.20M | -78.43M | 13.24M | |
| DepreciationAmortizationDepletionIncomeStatement | 7.70M | 92.16M | 97.45M | 95.00M |
| DepreciationAndAmortizationInIncomeStatement | 7.70M | 92.16M | 97.45M | 95.00M |
| Amortization | 7.70M | 92.16M | 97.45M | 95.00M |
| AmortizationOfIntangiblesIncomeStatement | 7.70M | 92.16M | 97.45M | 95.00M |
| ResearchAndDevelopment | 523.00M | 431.21M | 426.93M | 394.19M |
| SellingGeneralAndAdministration | 1.94B | 1.68B | 1.63B | 1.59B |
| SellingAndMarketingExpense | 1.05B | 894.12M | 827.80M | 929.64M |
| GeneralAndAdministrativeExpense | 888.67M | 781.83M | 800.29M | 663.38M |
| OtherGandA | 888.67M | 781.83M | 800.29M | 663.38M |
| SalariesAndWages | 1.00B | 977.80M | 989.50M | 533.10M |
| GrossProfit | 2.26B | 1.92B | 1.76B | 1.42B |
| CostOfRevenue | 984.24M | 840.15M | 737.56M | 661.36M |
| TotalRevenue | 3.25B | 2.76B | 2.50B | 2.08B |
| OperatingRevenue | 3.25B | 2.76B | 2.50B | 2.08B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 190.80M | 185.62M | 181.36M | 177.93M |
| ShareIssued | 190.80M | 185.62M | 181.36M | 177.93M |
| NetDebt | 1.37B | 1.97B | 1.76B | 1.99B |
| TotalDebt | 2.52B | 2.75B | 2.55B | 2.45B |
| TangibleBookValue | -886.92M | -974.12M | -1.11B | -1.26B |
| InvestedCapital | 4.73B | 4.97B | 5.51B | 5.28B |
| WorkingCapital | 914.70M | 839.24M | 679.67M | 569.51M |
| NetTangibleAssets | -886.92M | -974.12M | -1.11B | -1.26B |
| CapitalLeaseObligations | 195.52M | 184.54M | 190.45M | 210.76M |
| CommonStockEquity | 2.40B | 2.40B | 3.15B | 3.04B |
| TotalCapitalization | 4.73B | 4.72B | 5.46B | 5.28B |
| TotalEquityGrossMinorityInterest | 2.40B | 2.40B | 3.15B | 3.04B |
| StockholdersEquity | 2.40B | 2.40B | 3.15B | 3.04B |
| GainsLossesNotAffectingRetainedEarnings | 2.36M | -944.00K | 1.43M | -5.24M |
| OtherEquityAdjustments | 2.36M | -944.00K | 1.43M | -5.24M |
| RetainedEarnings | -4.71B | -4.50B | -3.47B | -3.27B |
| AdditionalPaidInCapital | 7.10B | 6.90B | 6.61B | 6.31B |
| CapitalStock | 1.91M | 1.86M | 1.81M | 1.78M |
| CommonStock | 1.91M | 1.86M | 1.81M | 1.78M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.46B | 3.53B | 3.33B | 3.18B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.82B | 2.79B | 2.81B | 2.77B |
| OtherNonCurrentLiabilities | 329.32M | 315.50M | 335.98M | 352.46M |
| LongTermDebtAndCapitalLeaseObligation | 2.49B | 2.48B | 2.48B | 2.42B |
| LongTermCapitalLeaseObligation | 161.93M | 157.13M | 161.07M | 182.40M |
| LongTermDebt | 2.33B | 2.32B | 2.31B | 2.24B |
| CurrentLiabilities | 641.15M | 732.19M | 514.70M | 412.75M |
| OtherCurrentLiabilities | 15.22M | 37.77M | 14.82M | 10.25M |
| CurrentDebtAndCapitalLeaseObligation | 33.59M | 276.56M | 79.38M | 28.37M |
| CurrentCapitalLeaseObligation | 33.59M | 27.41M | 29.38M | 28.37M |
| CurrentDebt | 249.15M | 50.00M | ||
| OtherCurrentBorrowings | 249.15M | 50.00M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 276.66M | 185.93M | 247.62M | 201.25M |
| PayablesAndAccruedExpenses | 315.68M | 231.93M | 172.88M | 172.88M |
| CurrentAccruedExpenses | 139.81M | 142.36M | 94.06M | 97.96M |
| Payables | 175.87M | 89.57M | 78.82M | 74.92M |
| AccountsPayable | 175.87M | 89.57M | 78.82M | 74.92M |
| TotalAssets | 5.86B | 5.93B | 6.47B | 6.23B |
| TotalNonCurrentAssets | 4.30B | 4.36B | 5.28B | 5.24B |
| OtherNonCurrentAssets | 185.81M | 169.72M | 177.39M | 90.58M |
| GoodwillAndOtherIntangibleAssets | 3.29B | 3.38B | 4.26B | 4.30B |
| OtherIntangibleAssets | 919.92M | 1.01B | 1.89B | 1.96B |
| Goodwill | 2.37B | 2.37B | 2.37B | 2.35B |
| NetPPE | 831.00M | 810.62M | 842.06M | 851.76M |
| AccumulatedDepreciation | -604.13M | -508.57M | -417.20M | -307.59M |
| GrossPPE | 1.44B | 1.32B | 1.26B | 1.16B |
| Leases | 257.50M | 227.88M | 214.56M | 200.59M |
| ConstructionInProgress | 84.14M | 89.06M | 104.59M | 68.40M |
| OtherProperties | 122.33M | 116.95M | 143.71M | 167.00M |
| MachineryFurnitureEquipment | 668.91M | 583.06M | 494.18M | 423.29M |
| BuildingsAndImprovements | 290.78M | 290.78M | 290.78M | 288.94M |
| LandAndImprovements | 11.46M | 11.46M | 11.45M | 11.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.56B | 1.57B | 1.19B | 982.26M |
| OtherCurrentAssets | 126.28M | 122.05M | 85.63M | 73.90M |
| PrepaidAssets | 74.12M | |||
| Inventory | 166.20M | 162.38M | 127.47M | 118.26M |
| FinishedGoods | 57.05M | 53.67M | ||
| WorkInProcess | 90.48M | 92.65M | 68.88M | 57.05M |
| RawMaterials | 75.72M | 69.73M | 58.59M | 61.21M |
| Receivables | 298.65M | 248.97M | 203.62M | 158.04M |
| AccountsReceivable | 298.65M | 248.97M | 203.62M | 158.04M |
| CashCashEquivalentsAndShortTermInvestments | 964.71M | 1.04B | 777.64M | 632.06M |
| OtherShortTermInvestments | 8.71M | 437.14M | 172.27M | 389.56M |
| CashAndCashEquivalents | 956.00M | 600.89M | 605.38M | 242.49M |
| CashEquivalents | 0.00 | 5.34M | 75.28M | 64.33M |
| CashFinancial | 956.00M | 595.55M | 530.10M | 178.17M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 356.78M | 74.55M | 31.93M | -438.02M |
| RepaymentOfDebt | -249.17M | -50.00M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 266.75M | 137.98M | 50.00M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -134.66M | -135.99M | -124.19M | -214.46M |
| InterestPaidSupplementalData | 30.44M | 27.84M | 18.78M | 11.52M |
| EndCashPosition | 956.00M | 606.64M | 609.67M | 242.79M |
| BeginningCashPosition | 606.64M | 609.67M | 242.79M | 315.77M |
| EffectOfExchangeRateChanges | 891.00K | -3.29M | 1.32M | 30.00K |
| ChangesInCash | 348.47M | 255.00K | 365.56M | -73.01M |
| FinancingCashFlow | -338.09M | 231.87M | 159.77M | 76.48M |
| CashFlowFromContinuingFinancingActivities | -338.09M | 231.87M | 159.77M | 76.48M |
| NetOtherFinancingCharges | -117.36M | -17.75M | -9.75M | -5.53M |
| ProceedsFromStockOptionExercised | 28.45M | 32.88M | 31.54M | 32.02M |
| NetCommonStockIssuance | 0.00 | 0.00 | ||
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | -249.17M | 216.75M | 137.98M | 50.00M |
| NetLongTermDebtIssuance | -249.17M | 216.75M | 137.98M | 50.00M |
| LongTermDebtPayments | -249.17M | -50.00M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 266.75M | 137.98M | 50.00M |
| InvestingCashFlow | 195.12M | -442.15M | 49.68M | 74.07M |
| CashFlowFromContinuingInvestingActivities | 195.12M | -442.15M | 49.68M | 74.07M |
| NetOtherInvestingChanges | -46.73M | -45.23M | -250.00K | 24.45M |
| NetInvestmentPurchaseAndSale | 376.51M | -260.94M | 226.53M | 278.76M |
| SaleOfInvestment | 572.28M | 205.82M | 382.95M | 453.07M |
| PurchaseOfInvestment | -195.77M | -466.76M | -156.42M | -174.31M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -52.41M | -14.69M |
| PurchaseOfBusiness | 0.00 | 0.00 | -52.41M | -14.69M |
| NetPPEPurchaseAndSale | -134.66M | -135.99M | -124.19M | -214.46M |
| PurchaseOfPPE | -134.66M | -135.99M | -124.19M | -214.46M |
| OperatingCashFlow | 491.44M | 210.54M | 156.12M | -223.56M |
| CashFlowFromContinuingOperatingActivities | 491.44M | 210.54M | 156.12M | -223.56M |
| ChangeInWorkingCapital | 121.83M | -56.01M | -342.00K | -26.38M |
| ChangeInOtherWorkingCapital | -1.41M | -57.94M | ||
| ChangeInOtherCurrentLiabilities | -33.76M | -16.06M | -20.37M | -21.97M |
| ChangeInOtherCurrentAssets | -5.79M | -2.32M | -11.62M | -84.00K |
| ChangeInPayablesAndAccruedExpense | 214.04M | 43.54M | 82.75M | -52.18M |
| ChangeInInventory | -3.77M | -34.91M | -7.69M | -13.23M |
| ChangeInReceivables | -48.89M | -46.26M | -43.42M | 61.09M |
| ChangesInAccountReceivables | -48.89M | -46.26M | -43.42M | 61.09M |
| OtherNonCashItems | 135.74M | 13.86M | -62.55M | -17.14M |
| StockBasedCompensation | 217.67M | 214.88M | 231.31M | 206.82M |
| UnrealizedGainLossOnInvestmentSecurities | 11.77M | 1.49M | ||
| AssetImpairmentCharge | 7.20M | 869.46M | 621.00K | 15.97M |
| AmortizationOfSecurities | 1.84M | 4.62M | ||
| DeferredTax | -1.54M | -10.12M | -955.00K | -11.90M |
| DeferredIncomeTax | -1.54M | -10.12M | -955.00K | -11.90M |
| DepreciationAmortizationDepletion | 221.58M | 214.86M | 206.61M | 197.56M |
| DepreciationAndAmortization | 221.58M | 214.86M | 206.61M | 197.56M |
| AmortizationCashFlow | 96.70M | 95.16M | 92.16M | 97.45M |
| AmortizationOfIntangibles | 96.70M | 95.16M | 92.16M | 97.45M |
| Depreciation | 124.88M | 119.70M | 114.45M | 100.11M |
| OperatingGainsLosses | -3.08M | -7.54M | -14.42M | 35.02M |
| GainLossOnInvestmentSecurities | -3.08M | 2.71M | -4.10M | 21.77M |
| GainLossOnSaleOfPPE | 1.86M | 1.05M | ||
| NetIncomeFromContinuingOperations | -207.95M | -1.03B | -204.15M | -623.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EXAS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|